Stock analysts at StockNews.com started coverage on shares of Cumulus Media (NASDAQ:CMLS – Get Free Report) in a research note issued on Tuesday. The firm set a “hold” rating on the stock.
Cumulus Media Price Performance
CMLS stock opened at $0.93 on Tuesday. The firm has a market capitalization of $15.75 million, a P/E ratio of -0.11 and a beta of 1.45. Cumulus Media has a 52 week low of $0.88 and a 52 week high of $5.51. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 3.55. The company has a fifty day simple moving average of $1.38 and a two-hundred day simple moving average of $1.89.
Cumulus Media (NASDAQ:CMLS – Get Free Report) last announced its earnings results on Friday, August 2nd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.19). Cumulus Media had a negative net margin of 16.46% and a negative return on equity of 22.15%. The business had revenue of $204.85 million for the quarter, compared to analysts’ expectations of $206.00 million. During the same quarter last year, the firm earned ($0.06) EPS. Analysts anticipate that Cumulus Media will post -2.42 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Cumulus Media Company Profile
Cumulus Media Inc, an audio-first media company, owns and operates radio stations in the United States. It owns and operates stations in various markets, as well as affiliated stations through Westwood One. The company's content portfolio includes sports, news, talk, and entertainment programming from various brands, including the NFL, the NCAA, the Masters, CNN, AP News, the Academy of Country Music Awards, and other partners.
Featured Articles
- Five stocks we like better than Cumulus Media
- How to Use the MarketBeat Excel Dividend Calculator
- Intel: Is Now the Time to Be Brave?Â
- What to Know About Investing in Penny Stocks
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is a support level?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Cumulus Media Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumulus Media and related companies with MarketBeat.com's FREE daily email newsletter.